NCT00232635CompletedPhase 2
A Double-blind, Randomised, Placebo-controlled Study to Evaluate the Safety and Efficacy of A-60444 in Adults With RSV Infection Following Stem Cell Transplantation
Arrow Therapeutics1 site in 1 country27 target enrollmentStarted: September 1, 2005Last updated:
Conditions
Drugs
Trial Snapshot
- Phase
- Phase 2
- Status
- Completed
- Sponsor
- Enrollment
- 27
- Locations
- 1
- Primary Endpoint
- Reduction of viral load over time:
Study Overview
Brief Summary
Objectives
Primary Objectives:
- Pilot Study: A preliminary assessment of the exposure and safety of oral A-60444 in post-stem cell transplant patients with RSV infection.
- Main Study: To determine the antiviral effect of oral A-60444 versus placebo in post-stem cell transplant patients with RSV infection and to assess the safety of oral A-60444 in post-stem cell transplant patients with RSV infection.
Secondary Objectives:
- To study the pharmacokinetics of A-60444 in the presence of concomitant medications such as immunosuppressants and antifungals, in post-stem cell transplant patients with RSV infection.
Sample Size: Six patients will be included in the open, pilot phase of the study and there is an option to include a further 22 patients into the main, placebo-controlled study, depending on the pilot study findings. An independent Data Safety Monitoring Board will assess the findings of the pilot study.
Detailed Description
Clinical will be recorded daily. A-60444 PK will be studied pre-dose and at peak dose on the last day (Day 5) of dosing.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Eligibility Criteria
- Ages
- 18 Years to 65 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Patients diagnosed with RSV infection who have had a stem cell transplant.
- •Female patients must be of non-childbearing potential or have a negative pregnancy test prior to study start and be deemed not at risk of becoming pregnant. Females of non-childbearing potential are defined as women who have had a hysterectomy, bilateral oophorectomy, tubal ligation, or who have been post-menopausal for at least two years; or are considered to be sterile due to recent chemotherapy.
- •Aged between 18 and 65 years.
- •Patients who have given their written informed consent to participate in the study.
- •Patients who are willing and able to comply with the protocol and study procedures.
Exclusion Criteria
- •Patients who have received an investigational drug within one month preceding the start of dosing.
- •Patients who have a documented history of allergy to benzodiazepines.
- •Patients with significant hepatic impairment (alanine transaminase [ALT] more than 5 x upper level of normal [ULN], total bilirubin more than 3 x ULN). Biochemistry data collected four weeks prior to screening is acceptable.
- •Patients, who in the opinion of their general practitioner or the Investigator, should not participate in the study.
Outcomes
Primary Outcomes
Reduction of viral load over time:
2-log reduction (by quantitative real time reverse transcription polymerase chain reaction [rtRT PCR]) in the RSV load of nasopharyngeal swabs in patients three days after treatment with A-60444, compared to patients treated with placebo
Secondary Outcomes
- Change in viral titre over treatment period
- Safety, pharmacokinetics (PK)
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Completed
Phase 1
A Study of the Safety, Tolerability, Pharmacokinetics and Food Effect After Single and Multiple Ascending Oral DosesAutoimmune DiseasesNCT05218434Artax Biopharma Inc64
Active, not recruiting
Phase 1
GDNF Gene Therapy for Multiple System AtrophyMultiple System AtrophyNCT04680065Brain Neurotherapy Bio, Inc.9
Completed
Phase 1
Fecal Microbiota Transplant (FMT) in Pediatric Active Ulcerative Colitis and Pediatric Active Crohn's ColitisInflammatory Bowel DiseasesUlcerative ColitisCrohn DiseaseNCT02330653Stacy A. Kahn15
Completed
Phase 2
A Double-blind Randomized Placebo-controlled Study Study of the Safety, Reactogenicity and Immunogenicity of the GamFluVacHealthy VolunteersNCT04034290Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation224
Completed
Not Applicable
Study Evaluating the Safety and Tolerability of a ProbioitcHealthy VolunteersTolerabilitySafetyNCT05044949BioGaia AB35